Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.34 |
| ▸ | GAA | P10253 | 2/20 | 0.33 |
| ▸ | MEN1 | O00255 | 4/20 | 0.31 |
| ▸ | KMT2A | Q03164 | 4/20 | 0.31 |
| ▸ | MAPT | P10636 | 2/20 | 0.31 |
| ▸ | LMNA | P02545 | 1/20 | 0.31 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.31 |
| ▸ | TSHR | P16473 | 1/20 | 0.31 |
| ▸ | INSR | P06213 | 1/20 | 0.30 |
| ▸ | IGF1R | P08069 | 1/20 | 0.30 |
| ▸ | ALK | Q9UM73 | 1/20 | 0.30 |
| ▸ | RAB9A | P51151 | 1/20 | 0.30 |
| ▸ | HPGD | P15428 | 1/20 | 0.30 |
| ▸ | CASP1 | P29466 | 1/20 | 0.30 |
| ▸ | POLB | P06746 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL30871276 | 0.83 | INSR (0.41) | GAAMEN1KMT2AMAPTLMNA | |
| SCHEMBL25033063 | 0.83 | INSR (0.41) | GAAMEN1KMT2AMAPTLMNA | |
| SCHEMBL29212352 | 0.83 | INSR (0.33) | INSRIGF1RALK | |
| SCHEMBL30184488 | 0.83 | INSR (0.33) | INSRIGF1RALK | |
| SCHEMBL25033612 | 0.81 | INSR (0.32) | SMN1; SMN2MEN1KMT2AMAPTTSHR | |
| SCHEMBL30184541 | 0.80 | INSR (0.35) | INSRIGF1RALK | |
| SCHEMBL25033233 | 0.80 | MAOA (0.30) | — | |
| SCHEMBL30184645 | 0.80 | MAOA (0.30) | — | |
| SCHEMBL25030921 | 0.77 | MAPT (0.31) | MAPT | |
| SCHEMBL30871078 | 0.77 | SMN1; SMN2 (0.43) | SMN1; SMN2GAAMEN1KMT2AMAPT |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-4676602-A1 | COMPOUNDS TARGETING MUTATIONS IN P53 AND USES THEREOF | Merck Sharp & Dohme LLC (US) | 2026-01-14 | — | — | EP | disclosed |
| US-20240400591-A1 | COMPOUNDS TARGETING MUTANT OF P53 | JACOBIO PHARMACEUTICALS CO., LTD. (CN) | 2024-12-05 | — | — | US | disclosed |
| WO-2024187153-A1 | COMPOUNDS TARGETING MUTATIONS IN P53 AND USES THEREOF | MERCK SHARP & DOHME LLC (US) | 2024-09-12 | — | — | WO | disclosed |
| EP-4384510-A1 | COMPOUNDS TARGETING MUTANT OF P53 | Jacobio Pharmaceuticals Co., Ltd. (CN) | 2024-06-19 | — | — | EP | disclosed |
| CN-117813295-A | Compounds targeting p53 mutants | 北京加科思新药研发有限公司 | 2024-04-02 | — | — | CN | disclosed |
| WO-2023016434-A1 | COMPOUNDS TARGETING MUTANT OF P53 | JACOBIO PHARMACEUTICALS CO., LTD. (CN) | 2023-02-16 | — | — | WO | disclosed |
| WO-2023016434-A1 | COMPOUNDS TARGETING MUTANT OF P53 | JACOBIO PHARMACEUTICALS CO., LTD. (CN) | 2023-02-16 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20240400591-A1 | COMPOUNDS TARGETING MUTANT OF P53 | TP53, TP53BP1, MDM2 | SMN1; SMN2 4553/4885GAA 852/4885MEN1 3802/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.